title: Development of a chitosan-based nanoparticle formulation for delivery of a hydrophilic hexapeptide, dalargin.
abstract: Nanoparticle based delivery systems can offer opportunities for targeting, controlled release, and enhanced stability of their drug, protein, or gene therapy payload. This study investigated the use of chitosan in combination with the ionic additives sulfobutyl-ether-7-beta-cyclodextrin (SB-CD) or SB-CD/dextran sulfate (SB-CD/DS) mixture in comparison with chitosan: DS in the formulation of nanoparticles incorporating the hexapeptide dalargin. The physical characteristics (particle size, zeta potential), entrapment and loading efficiency, and release of dalargin were quantified. It was demonstrated that anionic cyclodextrin, SB-CD, can be used in complex coacervation with chitosan, with and without the presence of DS, to form nanoparticles. The presence of SB-CD or DS in the nanoparticle formulation and the weight ratio of chitosan to anionic additive(s) influenced the physical properties of the nanoparticles and their ability to carry dalargin. In addition, the particle size of nanoparticles was also affected by the molecular weight of chitosan and DS. The use of either DS or SB-CD/DS mixture produced chitosan nanoparticles with small particle size, high dalargin entrapment efficiency, enhanced peptide stability, and sustained release characteristics.
authors.affiliation: School of Pharmacy, Curtin University of Technology, Perth, WA, Australia. y.chen@curtin.edu.au
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Basavaraj
authors.initials: B
authors.lastname: Siddalingappa
authors.forename: Phoebe H H
authors.initials: PH
authors.lastname: Chan
authors.forename: Heather A E
authors.initials: HA
authors.lastname: Benson
mesh_terms: D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000008:administration & dosage* / Q000737:chemistry; D016264:Dextran Sulfate / Q000008:administration & dosage / Q000737:chemistry; D004304:Dosage Forms; D016503:Drug Delivery Systems; D016308:Enkephalin, Leucine-2-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D008970:Molecular Weight; D053758:Nanoparticles / Q000008:administration & dosage*; D010316:Particle Size; D047392:beta-Cyclodextrins / Q000008:administration & dosage / Q000737:chemistry
chemical_list: D004304:Dosage Forms; D047392:beta-Cyclodextrins; C093196:SBE4-beta-cyclodextrin; D016308:Enkephalin, Leucine-2-Alanine; D048271:Chitosan; D016264:Dextran Sulfate; C040996:enkephalin-Leu, Ala(2)-Arg(6)-